Articles tagged with Vaccine Development
Researchers developed a two-part vaccination method that prevented genital herpes infection in mice, with 80% of treated mice showing no signs of disease. The 'prime and pull' approach uses nanoparticles to stimulate local immunity, establishing strong immune cell and antibody responses against the virus.
A new dual vaccine against Lassa fever and rabies has been shown to be safe and induce immune responses against both viruses. The vaccine could potentially streamline delivery in settings where access is limited, reducing the need for separate vaccination efforts.
The ACT-CHIK project will conduct a Phase Ib/III clinical trial to evaluate the safety and immunogenicity of a measles-virus-based chikungunya vaccine in four African countries. The project also aims to strengthen Africa's vaccine ecosystem by transferring the vaccine manufacturing process to an African manufacturer.
A study published in JAMA Network Open found that maternal RSV vaccination reduces hospitalization risk in young infants by nearly 70%. The vaccine also showed effectiveness against severe lung infections caused by the virus.
A universal Sarbeco coronavirus vaccine has shown safety and no significant side effects in a human clinical trial, providing protection against multiple viruses, including SARS-CoV-2. The vaccine uses an AI-designed super-antigen to offer lasting protection against emerging virus threats.
The new vaccine adjuvant induces a strong mucosal immune response in the GI tract, which is crucial for eradicating polio. The researchers achieved a 20-fold increase in antibodies needed for mucosal immunity compared to the existing injectable polio vaccine.
A new leishmaniasis vaccine, developed using CRISPR gene-editing technology, is set to begin testing in healthy people for its safety and immune response. The vaccine has shown strong results in mice and has cleared a key FDA hurdle, paving the way for Phase 2 trials aiming to understand its effectiveness.
Researchers at Southwest Research Institute (SwRI) and Texas Biomedical have identified nearly two dozen antiviral compounds that could potentially treat Bundibugyo Ebolavirus. The project utilizes AI and machine learning tools to quickly identify drug candidates, with Texas Biomed set to screen the compounds in the coming weeks.
Researchers have discovered the missing genes and enzyme that tobacco plants need to make nicotine, solving a mystery that has puzzled scientists for nearly two centuries. The discovery could lead to safer production of medicines and vaccines using tobacco plants, without the unwanted nicotine.
A new mRNA-based strategy amplifies the T-cell response to vaccines, enabling more powerful cancer vaccines and stronger protection against infectious diseases. The approach reprograms immune cells from within using mRNA instructions that expand cancer-fighting T cells.
A phase 2 human clinical trial of a hookworm antigen has shown effective in limiting the intensity of infection, paving the way for a vaccine. The study found that vaccination with Na-GST-1 reduced the severity of infection in participants.
A new vaccine strategy has generated antibodies capable of neutralising highly divergent HIV variants in an animal model. The study provides new insights into how the immune system can be guided towards a particularly protected part of the virus, which is important for developing an effective HIV vaccine.
A nationally representative survey found that nearly 7 in 10 people trust vaccine scientists to act in their best interests, similar to medical scientists and scientists in general. The public perceives vaccine scientists as credible, self-correcting, and unbiased, with their work benefiting society.
Researchers at the University of Nebraska-Lincoln have developed a promising new vaccine approach against highly pathogenic bird flu (H5N1) that demonstrates strong efficacy in both mice and dairy cattle. The vaccine platform protects against multiple H5N1 strains and generates immunity in both the bloodstream and respiratory tract.
Researchers developed a new flu vaccine approach targeting specific but distinct regions of the influenza virus protein. This method broadened the immune response, leading to broader protection against various strains. The study's findings have implications for fighting other fast-changing viruses like COVID-19 and RSV.
Researchers have found that COVID vaccines can train immune cells to remember the SARS-CoV-2 virus and protect against severe infection for years afterward. However, the continued spread of disease has scientists taking a closer look at how the immune system builds up immune memory over time.
Researchers found that obesity significantly impaired antibody production to a Pseudomonas aeruginosa vaccine in mouse models. The study suggests prioritizing tissue-resident immunity to boost protection against infections. Understanding this relationship addresses a significant gap in current vaccine research.
Researchers found that squalene-based adjuvants activate distinct pathways for vaccine protection and reactogenicity, including the role of IL-1β in enhancing efficacy and IL-1α in triggering local swelling. The study's findings could lead to safer vaccine design by targeting specific immune mechanisms.
Researchers at Scripps Research create a nanodisc platform that preserves key parts of viral surface proteins, allowing for better understanding of antibody interactions. This approach can be applied to other viruses with similar membrane-embedded proteins, such as influenza and SARS-CoV-2.
A novel flu vaccine platform uses cell-derived extracellular vesicles to induce cross-protective immunity against influenza virus infections. The vaccine shows promise as an effective mucosal vaccine strategy.
Researchers at Karolinska Institutet have mapped immune gene variation across multiple global populations, identifying common genetic variants that affect antibody production. The findings may contribute to understanding infection susceptibility and inform vaccine design.
Researchers redesigned a key component of lipid nanoparticles to steer particles toward lymph nodes, reducing off-target delivery. This advancement could make mRNA vaccines more efficient, potentially achieving strong immune protection at lower doses.
Researchers at the University of Pennsylvania developed lipid nanoparticles that modify immune metabolism to strengthen mRNA vaccines and reduce common side effects. The new lipid boosts the metabolism of immune cells, providing energy for the body's defenses while dialing down inflammatory signals.
The Butantan-DV dengue vaccine, developed in Brazil, shows 80.5% effectiveness against severe cases over five years, with no hospitalizations in the vaccinated group. The vaccine was 65% effective in preventing symptomatic dengue during the five-year monitoring period.
Researchers at the Wyss Institute developed DoriVac, a DNA nanotechnology-enabled vaccine platform that induces broad immunity against infectious viruses, including SARS-CoV-2, HIV, and Ebola. The platform produces potent antigen-specific immune responses and is more stable and easier to manufacture than traditional vaccine platforms.
A new study discovered that a multifaceted infection prevention and control intervention successfully disrupted a large and long-running bacterial outbreak of Klebsiella pneumoniae in a Zambian neonatal intensive care unit. The study found that low-cost measures, including IPC training, enhanced cleaning, and hand hygiene, reduced neon...
A Purdue University-developed contraceptive vaccine reduces fertility in feral horses, deer, swine, and other animals, overcoming limitations of existing models. The vaccine, based on a male sperm protein, induces a long-lasting immune response and infertility in female mammals, with promising results for wildlife management.
The study found that the intranasal vaccine booster Clec9A OMNI induced significantly stronger neutralising antibody responses and robust T-cell responses in the lungs and nasal tissues, offering robust protection against SARS-CoV-2 Omicron infection. This breakthrough may address current shortcomings of COVID-19 mRNA vaccines, includi...
Researchers developed a universal vaccine formula that provides broad protection against respiratory viruses, bacteria and even allergens. The vaccine is delivered intranasally and works for a wide spectrum of respiratory threats, including SARS-CoV-2 and common hospital-acquired infections.
A novel vaccination approach cleared harmful gut bacterium Clostridioides difficile (C. diff) in an animal model of infection. The experimental vaccine protected against illness, death, tissue damage and infection recurrence through mucosal immunization.
Researchers at Ragon Institute discovered that antibodies produced in germinal centers act as a 'brake' on selection, redirecting the immune system toward broader protection. Stronger-binding B cells suppress weaker ones targeting the same site, establishing a localized feedback loop.
A new HPV cancer vaccine developed by Northwestern University scientists has shown promising results in a preclinical model. The vaccine's carefully organized structure dramatically enhances the immune system's ability to attack tumors, shrinking them and extending animal survival.
Researchers have identified a molecular trigger for rare blood clotting conditions after COVID19 adenovirus-based vaccines or natural adenovirus infections. The exact cause is now understood, allowing vaccine developers to adjust the adenovirus protein and prevent this extremely rare reaction.
The partnership aims to develop next-generation mRNA vaccines with enhanced stability and targeted delivery, providing broader protection against emerging pathogens. This collaboration combines Ethris' mRNA technology platforms with DZIF's vaccine research expertise to accelerate the development of variant-ready vaccines.
A team of researchers at Binghamton University is developing a new yeast-based solution for the production of better avian flu vaccines. The project aims to improve manufacturing, storage, and transportation efficiency compared to current options.
Researchers developed an intranasal vaccine that elicited strong immune responses and prevented infections in exposed animals, providing protection against upper respiratory infection and severe disease. The nasal vaccine was effective regardless of prior flu exposure, making it a promising tool in the fight against H5N1 bird flu.
The new platform developed by UVA Health scientists can produce vaccines much faster, cheaper, and more easily than traditional approaches. The platform's proof-of-concept demonstrates its ability to produce highly immunogenic vaccines that can be manufactured at extremely low cost.
A new MERS vaccine candidate has shown a stable and functional immune response in humans that persists for at least two years after a booster vaccination. The study demonstrates that such durable immunity can be achieved through targeted booster vaccinations, providing an important step toward an effective MERS vaccine.
Researchers developed a new system that efficiently transfects targeted immune cells, supports antigen presentation and immune cell maturation, and successfully crosses the mucus barrier in lung models. This breakthrough offers a promising alternative to lipid nanoparticles for next-generation pulmonary mRNA vaccines.
A single-dose oral cholera vaccine called PanChol has completed a phase 1 clinical trial with positive results, offering hope for combating the devastating disease globally. The vaccine was developed by Mass General Brigham and shows promise in preventing severe vomiting and diarrhea caused by Vibrio cholerae bacteria.
A study published in JAMA found that nirsevimab was associated with lower risks of RSV-related hospitalization and severe outcomes compared to maternal vaccination with the RSVpreF vaccine. These findings suggest a potential benefit for passive infant immunization with nirsevimab in reducing RSV-related complications.
Researchers at Tulane University have developed the first vaccine able to protect nonhuman primates from melioidosis, a long-neglected and deadly tropical disease on the rise. The vaccine uses outer membrane vesicles to trigger a powerful immune response.
Two new Cochrane reviews show that HPV vaccines are effective in preventing cervical cancer and pre-cancerous changes, especially when given to young people before they are exposed to the virus. Girls vaccinated before the age of 16 were found to be 80% less likely to develop cervical cancer.
Scientists have developed a fast-acting and long-lasting vaccine against Crimean-Congo hemorrhagic fever (CCHF), which is one of the world's most dangerous infectious diseases. The vaccine, made from a virus-like replicon particle, provides durable humoral immunity for up to 18 months.
Researchers discovered a 'sticky' molecule, P-selectin, that can cause blood clots and organ failure during COVID-19. A new mRNA therapy that drives P-selectin expression provides broad protection against coronavirus infection.
Cynthia Nau Cornelissen has received nearly $7 million in federal grants to combat sexually transmitted infections (STIs), particularly gonorrhea. The researcher will study the human-specific pathogen Neisseria gonorrhoeae and develop vaccines and therapeutics using innovative approaches.
The Phase 3 study demonstrated the safety and non-inferiority of EuTYPH-C Inj.® Multi-dose compared to a World Health Organization (WHO) prequalified comparator TCV, Typbar TCV®. The vaccine was shown to be well-tolerated across all age groups with no serious adverse events.
A new nasally-delivered vaccine has been shown to prevent severe disease and curb bacterial transmission, addressing a global need for next-generation immunisation technologies. The vaccine targets the respiratory mucosa, providing stronger protection against respiratory infections.
Researchers have developed particles that can deliver an effective immune response at a much lower dose than traditional mRNA vaccines. The new particles, called AMG1541, use cyclic structures and ester groups to enhance mRNA delivery and improve biodegradability. This could potentially reduce vaccine costs and side effects.
Researchers at the University of Maryland School of Medicine have reported encouraging results from an early phase clinical trial of an intranasal influenza vaccine. The study found that the vaccine triggered a broad immune response, including higher levels of protective antibodies and better ability to kill infected cells.
Researchers at MIT have identified possible antigens for a new TB vaccine, stimulating a strong immune response in T cells. The study reveals 27 TB peptides that appear most often on infected cell surfaces and elicit a T cell response in at least some samples.
Researchers have discovered that human astroviruses bind to a protein in human cells called the neonatal Fc receptor. The study provides a key target for vaccine development and repurposing of existing treatments.
Researchers have developed a novel vaccine strategy using biomaterial scaffold vaccines to protect against Staphylococcus aureus infections in orthopedic device implants. The vaccines, made with immune cell-attaching molecules and S. aureus-specific antigens, create a beneficial immune response that significantly lowers bacterial burden.
Scientists have characterized lipid nanoparticles' internal shape and structure, which correlates with how well they deliver therapeutic cargo. The research provides a blueprint for engineering more effective RNA therapies by matching LNP designs to specific therapies and tissues.
The ESMO Congress 2025 will cover key topics including precision oncology, antibody-drug conjugates in breast cancer, dose optimisation strategies, new treatment modalities for melanoma, and immunotherapy-based approaches across various cancer settings. Promising Phase-3 studies on ADCs in bladder and lung cancer are also expected.
Researchers have developed a new mRNA vaccine technology using albumin-recruiting lipid nanoparticles to deliver vaccines precisely to lymph nodes, avoiding liver toxicity. The approach outperformed traditional delivery systems in laboratory tests, producing strong antitumor T-cell responses and high levels of neutralizing antibodies.
A new vaccine against elephant endotheliotropic herpesvirus (EEHV) has been shown to be safe and trigger a strong immune response, with the potential to prevent deadly EEHV disease in young Asian elephants. The vaccine was tested in adult elephants at Chester Zoo and successfully activated key parts of the immune system.
A new herpes virus-based vaccine has been developed that targets cancer cells while sparing healthy tissue. The vaccine, which includes a gene encoding the protein decorin, was shown to enhance its cancer-killing effect on lung cancer cells and reduce tumour angiogenesis in liver cancer in chicken embryos.
A new mRNA vaccine has stopped allergens from causing immune reactions and inflammation in mice, instructing the immune system to respond more appropriately. The vaccine is tailored to encode proteins from different allergens, offering a flexible solution to treat seasonal pollen allergies, food sensitivities, and asthma.